These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32039536)

  • 1. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.
    Hsieh YC; Lin CL; Hung CH; Chen CH; Tung SY; Lin CY; Hu TH; Lu SN; Chien RN; Sheen IS
    J Viral Hepat; 2020 May; 27(5):505-513. PubMed ID: 32039536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
    Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    Zeuzem S; Serfaty L; Vierling J; Cheng W; George J; Sperl J; Strasser S; Kumada H; Hwang P; Robertson M; Wahl J; Barr E; Talwani R; Platt H
    J Gastroenterol; 2018 May; 53(5):679-688. PubMed ID: 29344726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
    Zeuzem S; Ghalib R; Reddy KR; Pockros PJ; Ben Ari Z; Zhao Y; Brown DD; Wan S; DiNubile MJ; Nguyen BY; Robertson MN; Wahl J; Barr E; Butterton JR
    Ann Intern Med; 2015 Jul; 163(1):1-13. PubMed ID: 25909356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
    Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.
    Liu CH; Peng CY; Fang YJ; Kao WY; Yang SS; Lin CK; Lai HC; Su WP; Fang SU; Chang CC; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
    Sci Rep; 2020 Jun; 10(1):9180. PubMed ID: 32513953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
    Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Hinrichsen H; Stoehr A; Cornberg M; Klinker H; Heyne R; John C; Simon KG; Guenther V; Martin K; Witte V; Zeuzem S
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):415-423. PubMed ID: 32345848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
    Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
    Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
    Wei L; Kumada H; Perumalswami PV; Tanwandee T; Cheng W; Heo J; Cheng PN; Hwang P; Mu SM; Zhao XM; Asante-Appiah E; Caro L; Hanna GJ; Robertson MN; Haber BA; Talwani R
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1597-1603. PubMed ID: 30779220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
    Boerekamps A; De Weggheleire A; van den Berk GE; Lauw FN; Claassen MAA; Posthouwer D; Bierman WF; Hullegie SJ; Popping S; van de Vijver DACM; Dofferhoff ASM; Kootstra GJ; Leyten EM; den Hollander J; van Kasteren ME; Soetekouw R; Ammerlaan HSM; Schinkel J; Florence E; Arends JE; Rijnders BJA
    Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):269-277. PubMed ID: 30660617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
    Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
    Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
    Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H; Martin P; Pol S; Londoño MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W
    Lancet; 2015 Oct; 386(10003):1537-45. PubMed ID: 26456905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
    Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
    Yao Y; Yue M; Wang J; Chen H; Liu M; Zang F; Li J; Zhang Y; Huang P; Yu R
    Can J Gastroenterol Hepatol; 2017; 2017():8186275. PubMed ID: 28164081
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
    Asselah T; Reesink H; Gerstoft J; de Ledinghen V; Pockros PJ; Robertson M; Hwang P; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Talwani R; Serfaty L
    Liver Int; 2018 Sep; 38(9):1583-1591. PubMed ID: 29461687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
    PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.